Axitinib
别名: AG 013736
中文名称:阿西替尼,阿昔替尼
目录号:S1005 Purity: 99.96%
Axitinib是一种多靶点抑制剂,作用于 VEGFR1,VEGFR2,VEGFR3,PDGFRβ和c-Kit,在猪主动脉内皮细胞中IC50分别为0.1 nM,0.2 nM,0.1-0.3 nM,1.6 nM和1.7 nM。
CAS: 319460-85-0
客户使用Selleck的Axitinib发表文献180篇
- Nat Neurosci, 2024 10.1038/s41593-024-01604-8
- Cancer Cell, 2022 40-10:1111-1127.e9
- Cancer Cell, 2022 S1535-6108(21)00662-0
- Mol Cancer, 2022 21(1):181
- Blood, 2022 blood.2021014304
- Cell, 2018 173(1):117-129
- Cell, 2018 173(1):74-89
- Cancer Discov, 2012 2(4):344-55
- Cell Rep Med, 2024 S2666-3791(24)00201-5
- EMBO Mol Med, 2024 10.1038/s44321-024-00094-2
- Elife, 2024 12RP92324
- Elife, 2024 12RP89080
- Front Cell Dev Biol, 2024 12:1356589
- Cancer Med, 2024 13(20):e70288
- Front Physiol, 2024 15:1397049
- World J Emerg Med, 2024 15(3):206-213
- Genesis, 2024 62(4):e23614
- J Exp Med, 2023 220(11)e20230011
- Theranostics, 2023 13(11):3744-3760
- Proc Natl Acad Sci U S A, 2023 120(21):e2209639120
- Cell Rep, 2023 S2211-1247(23)01614-5
- Cancer Sci, 2023 114(10):3946-3956
- Cancer Sci, 2023 114(4):1651-1662
- Burns Trauma, 2023 11:tkad003
- Invest Ophthalmol Vis Sci, 2023 10.1167/iovs.64.14.9
- J Cell Commun Signal, 2023 17(1):151-165
- Front Med (Lausanne), 2023 10:1256156
- Clin Cosmet Investig Dermatol, 2023 16:3023-3034
- Noncoding RNA, 2023 9(3)31
- Nat Commun, 2022 13(1):7113
- Theranostics, 2022 12(17):7351-7370
- J Control Release, 2022 347:449-459
- Acta Biomater, 2022 S1742-7061(22)00665-1
- Cell Rep, 2022 41(11):111827
- Acta Pharmacol Sin, 2022 10.1038/s41401-022-00907-5
- Oncogene, 2022 41(28):3655-3663
- mBio, 2022 e0123322
- Cells, 2022 11(9)1448
- Stem Cell Reports, 2022 S2213-6711(22)00206-5
- NPJ Breast Cancer, 2022 8(1):44
- iScience, 2022 25(7):104538
- J Ethnopharmacol, 2022 288:114969
- Oncotarget, 2022 13:281-290
- Mol Cancer Res, 2022 20(1):161-175
- Cancers (Basel), 2022 14(7)1639
- J Pers Med, 2022 12(2)258
- Sci Rep, 2022 12(1):17192
- Sci Rep, 2022 12(1):12546
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- J Pharm Sci, 2022 111(8):2180-2190
- Dev Biol, 2022 484:63-74
- Dev Dyn, 2022 10.1002/dvdy.474
- Sci Adv, 2022 8(6):eabg9455
- Sci Adv, 2022 8(2):eabi8683
- Nat Commun, 2021 12(1):808
- J Clin Invest, 2021 131(8)139434
- Theranostics, 2021 11(10):4975-4991
- Cancer Res, 2021 canres.2426.2020
- Mol Syst Biol, 2021 17(9):e10426
- Elife, 2021 10e67315
- Cancer Gene Ther, 2021 10.1038/s41417-021-00345-1
- J Clin Endocrinol Metab, 2021 dgab020
- Cancer Immunol Immunother, 2021 10.1007/s00262-021-02992-7
- Front Pharmacol, 2021 12:816477
- Int J Mol Sci, 2021 22(24)13352
- CNS Neurosci Ther, 2021 10.1111/cns.13788
- Oncotarget, 2021 12(7):674-685
- Oncotarget, 2021 12(19):1903-1919
- Cancers (Basel), 2021 14(1)70
- Cancers (Basel), 2021 13(9)2009
- Aging (Albany NY), 2021 13(19):22710-22731
- Biomedicines, 2021 9(8)949
- Biomedicines, 2021 9(6)627
- Front Oncol, 2021 11:650052
- Front Oncol, 2021 11:723966
- Sci Rep, 2021 11(1):20111
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Drug Metab Dispos, 2021 49(1):53-61
- Hum Mol Genet, 2021 ddab011
- Dev Biol, 2021 473:80-89
- Mol Cell, 2020 80(6):1104-1122.e9
- Biomaterials, 2020 237:119793
- Genome Med, 2020 18;12(1):17
- Clin Cancer Res, 2020 20 pii: clincanres
- Cell Rep, 2020 32(2):107906
- Br J Cancer, 2020 22
- Cancer Cell Int, 2020 19;20:58
- Front Cell Dev Biol, 2020 8:578
- J Cell Mol Med, 2020 24(4):2402-2415
- Burns Trauma, 2020 8:tkaa025
- Journal of Cellular and Molecular Medicine, 2020 2402-2415
- Cancers (Basel), 2020 12(11)E3172
- Aging (Albany NY), 2020 7;12(9):8221-8240
- Aging (Albany NY), 2020 13(1):1096-1119
- Neoplasia, 2020 22(10):470-483
- Molecules, 2020 26(1)E35
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Toxicol In Vitro, 2020 71:105063
- Exp Ther Med, 2020 19(2):1336-1342
- Dev Cell, 2019 48(2):151-166.e7
- J Exp Clin Cancer Res, 2019 38(1):322
- Proc Natl Acad Sci U S A, 2019 116(25):12353-12362
- Cancer Immunol Res, 2019 7(9):1523-1534
- ACS Appl Mater Interfaces, 2019 101021/acsami9b20178
- Pharmacol Res, 2019 144:292-305
- Cell Rep, 2019 28(9):2331-2344
- Int J Nanomedicine, 2019 14:441-455
- Int J Cancer, 2019 145(7):1991-2001
- Lab Chip, 2019 19(12):2071-2080
- Commun Biol, 2019 2:170
- Mol Cancer Ther, 2019 10.1158/1535-7163.MCT-18-1319
- J Cell Physiol, 2019 10.1002/jcp.28810
- J Cell Mol Med, 2019 23(2):920-933
- J Immunol, 2019 203(10):2630-2643
- Naunyn Schmiedebergs Arch Pharmacol, 2019 10.1007/s00210-019-01746-8
- Plast Reconstr Surg, 2019 143(1):126-135
- Hum Mol Genet, 2019 10.1093/hmg/ddz152
- Assay Drug Dev Technol, 2019 17(4):167-177
- bioRxiv, 2019 10.1101/680165
- Nat Commun, 2018 9(1):5009
- Cell Death Dis, 2018 9(10):974
- Mol Cancer Ther, 2018 17(7):1405-1415
- J Cell Physiol, 2018 233(3):2067-2074
- Am J Physiol Cell Physiol, 2018 314(5):C589-C602
- Oncotarget, 2018 9(89):35962-35973
- Cell Biol Int, 2018 42(11):1511-1522
- Oncol Lett, 2018 15(5):6107-6114
- Biomed Chromatogr, 2018 32(6):e4184
- Theranostics, 2017 7(16):3972-3988
- Cancer Res, 2017 77(5):1212-1226
- Proc Natl Acad Sci U S A, 2017 114(11):2934-2939
- Br J Cancer, 2017 117(5):e3
- Cell Chem Biol, 2017 24(7):858-869
- Oncogene, 2017 10.1038/onc.2017.132
- Cell Biosci, 2017 7:43
- Arch Toxicol, 2017 91(8):2921-2938
- Neural Regen Res, 2017 12(11):1816-1822
- Eur Radiol, 2017 27(3):918-926
- Oncotarget, 2017 9(5):5529-5544
- Front Oncol, 2017 7:182
- Hum Mol Genet, 2017 26(22):4375-4387
- Chem Biodivers, 2017 14(3)
- Nat Commun, 2016 7:11363
- Clin Cancer Res, 2016 22(8):1940-50
- Cancer Res, 2016 76(11):3200-10
- Cancer Res, 2016 76(1):117-26
- Proc Natl Acad Sci U S A, 2016 113(33):9339-44
- CNS Neurosci Ther, 2016 22(6):440-50
- Oncotarget, 2016 7(18-:25983-6002
- Cellular Signalling, 2016 19;28(6):652-662
- Sci Rep, 2016 6:24453
- PLoS Genet, 2016 12(9):e1006279
- J Immunol, 2016 197(2):504-16
- Tumour Biol, 2016 37(2):2481-96
- Mol Nutr Food Res, 2015 59(11):2255-66
- Sci Rep, 2015 5:16622
- Invest Ophthalmol Vis Sci, 2015 56(5):3140-8
- PLoS One, 2015 10(10):e0140310
- PLoS One, 2015 10(6):e0128897
- Anal Chem, 2014 86(17):8842-9
- Oncotarget, 2014 5(16):6801-15
- Drug Des Devel Ther, 2014 8:1107-23
- J Cell Biochem, 2014 10.1002/jcb.25066
- PLoS One, 2014 9(1):e85759
- Gene Expression Patterns, 2014 16(2):93-103
- J Nucl Med, 2013 54(9):1630-6
- Br J Cancer, 2013 110(4):894-8
- Sci Signal, 2013 6(271):ra25
- Development, 2013 140(20):4214-25
- Acta Oncol, 2013 53(5):637-45
- Histochem Cell Biol, 2013 139(3):431-45
- J Labelled Comp Radiopharm, 2013 56(2):42-9
- Glia, 2012 60(6):936-47
- Cancer Sci, 2012 103(3):433-8
- Mol Med, 2012 18:887-98
- Cells Tissues Organs, 2012 196(3):195-205
- J Biomol Screen, 2011 16(2):141-54
化学信息&溶解度
分子量 | 386.47 |
分子式 | C22H18N4OS |
CAS号 | 319460-85-0 |
Smiles | CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 26 mg/mL ( 67.27 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 40 mg/mL ( 103.5 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 35 mg/mL ( 90.56 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 41 mg/mL ( 106.08 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 26 mg/mL ( 67.27 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5% DMSO
40% PEG 300
5%Tween80
50%ddH2O
浓度:1.85mg/ml
(4.79mM)
操作示例:以1mL工作液为例,取50μL37mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
|
5% DMSO
95% Corn oil
浓度:0.2mg/ml
(0.52mM)
操作示例:以1 mL工作液为例,取50μL 4mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。